156 related articles for article (PubMed ID: 35220261)
1. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
[TBL] [Abstract][Full Text] [Related]
2. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
[TBL] [Abstract][Full Text] [Related]
3. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
[TBL] [Abstract][Full Text] [Related]
4. Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
Furubayashi N; Morokuma F; Tomoda T; Hori Y; Negishi T; Miura A; Komori H; Kuroiwa K; Nakamura M
Anticancer Res; 2022 Mar; 42(3):1571-1577. PubMed ID: 35220254
[TBL] [Abstract][Full Text] [Related]
5. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
6. Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Tomisaki I; Harada M; Sakano S; Terado M; Hamasuna R; Harada S; Matsumoto H; Akasaka S; Nagata Y; Minato A; Harada KI; Fujimoto N
Int J Urol; 2023 Sep; 30(9):738-745. PubMed ID: 36693764
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
Fukuokaya W; Kimura T; Komura K; Uchimoto T; Nishimura K; Yanagisawa T; Imai Y; Iwatani K; Ito K; Urabe F; Tsuzuki S; Kimura S; Terada N; Mukai S; Oyama Y; Abe H; Kamoto T; Azuma H; Miki J; Egawa S
Urol Oncol; 2022 Jul; 40(7):346.e1-346.e8. PubMed ID: 35346571
[TBL] [Abstract][Full Text] [Related]
8. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
[TBL] [Abstract][Full Text] [Related]
9. Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Yumioka T; Honda M; Shimizu R; Teraoka S; Yamaguchi N; Kawamoto B; Iwamoto H; Morizane S; Hikita K; Takenaka A
Anticancer Res; 2021 Nov; 41(11):5767-5773. PubMed ID: 34732450
[TBL] [Abstract][Full Text] [Related]
10. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Oct; 26(20):5487-5493. PubMed ID: 32933995
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
[TBL] [Abstract][Full Text] [Related]
13. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
[TBL] [Abstract][Full Text] [Related]
14. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study.
Fukushima H; Kijima T; Fukuda S; Moriyama S; Uehara S; Yasuda Y; Tanaka H; Yoshida S; Yokoyama M; Matsuoka Y; Saito K; Matsubara N; Numao N; Sakai Y; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
Cancer Med; 2020 Nov; 9(22):8355-8363. PubMed ID: 32886446
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma.
Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
Urol Oncol; 2021 Dec; 39(12):834.e21-834.e28. PubMed ID: 34284929
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Iida K; Naiki T; Etani T; Nagai T; Sugiyama Y; Isobe T; Aoki M; Nozaki S; Noda Y; Shimizu N; Tomiyama N; Gonda M; Kamiya H; Kubota H; Nakane A; Ando R; Kawai N; Yasui T
Sci Rep; 2024 Jan; 14(1):2520. PubMed ID: 38291115
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Chen S; Zhang N; Wang T; Zhang E; Wang X; Zheng J
Front Immunol; 2020; 11():1900. PubMed ID: 32983112
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
19. PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors.
Zhang S; Tian J; Wang X; Liu C
BMC Pulm Med; 2023 Nov; 23(1):438. PubMed ID: 37951887
[TBL] [Abstract][Full Text] [Related]
20. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
